Quick Answer
Citius Pharmaceuticals, Inc. reported R&D Expense of $9.16 million for fiscal year 2025.
Citius Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $9.16M | -23.1% |
| 2024 | $11.91M | -19.7% |
| 2023 | $14.82M | -16.1% |
| 2022 | $17.66M | +44.2% |
| 2021 | $12.24M | +38.9% |
| 2020 | $8.81M | +2.5% |
| 2019 | $8.60M | +31.0% |
| 2018 | $6.56M | +123.5% |
| 2017 | $2.94M | +0.1% |
| 2016 | $2.93M | +63.2% |
| 2015 | $1.80M | +312974.0% |
| 2014 | $574.00 | -99.9% |
| 2013 | $492.1K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $1.60M | -24.8% | -1.3% |
| June 30, 2025 | $1.62M | -41.3% | -57.0% |
| March 31, 2025 | $3.77M | +4.5% | +77.1% |
| December 31, 2024 | $2.13M | -18.9% | -93.6% |
| August 31, 2024 | $33.40M | — | +1108.5% |
| June 30, 2024 | $2.76M | -26.6% | -23.4% |
| March 31, 2024 | $3.61M | -23.7% | +37.5% |
| December 31, 2023 | $2.62M | -23.9% | -30.4% |
- Citius Pharmaceuticals, Inc. showed a decrease of -23.1% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Citius Pharmaceuticals, Inc.’s r&d expense has grown by 1760.6% (from $492.1 thousand to $9.16 million).
- The most recent figure is from Citius Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: